3
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lung Neoplasms
3
Breast Neoplasms
2
Skin Carcinoma
1
Pancreatic Neoplasms
1
Pancreatic Cancer Liver Metastases
1
Malignant Solid Neoplasm
1
Malignant Female Reproductive System Neoplasm
1
Leukemia, Myeloid, Acute
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Hepatitis B, Chronic
1
Hemorrhage
1
Disease
1
Colorectal Neoplasms
1
Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8
1
Carcinoma, Hepatocellular
1
Anastomotic Leak
1
Adenoma, Islet Cell
1
Interventions
lenvatinib
16
Bevacizumab
14
sintilimab
10
tislelizumab
9
apatinib
9
regorafenib
6
camrelizumab
6
donafenib
5
atezolizumab
5
Immune Checkpoint Inhibitors
4
Hepatectomy
4
cabozantinib
3
Radiosurgery
3
Capecitabine
3
spartalizumab
2
pembrolizumab
2
durvalumab
2
anlotinib
2
Surgical Procedures, Operative
2
Specimen Handling
2
Oxaliplatin
2
Observation
2
Magnetic Resonance Spectroscopy
2
Injections
2
Immunotherapy
2
Folfox protocol
2
Fecal Microbiota Transplantation
2
Electroporation
2
Blood Specimen Collection
2
ursodoxicoltaurine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Carcinoma, Hepatocellular
×
Methods
×
Clear all
NCT07120750
2025-08-13
PRTRAS 001
Shenzhen Third People's Hospital
Not yet recruiting
332 enrolled